Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?

On the contrary, FISSION study [4] including SOF plus ribavirin for genotype 2 had shown that ribavirin exposure was a significant factor for SVR (odds ratio 1.258). [...]another even more remarkable difference was that the IFNL4 gene (previous mistakenly refer to IL28B, rs12979860) C/C constituted...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and molecular hepatology 2018, 24(3), , pp.294-296
Main Author: Yeon, Jong Eun
Format: Article
Language:English
Subjects:
Anemia
Antiviral drugs
Body mass index
Chronic hepatitis C
Clinical significance
Genotype & phenotype
Genotype 2
Hepatitis C
Liver cirrhosis
Patients
Polymorphism
Ribavirin
Sofosbuvir
내과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:On the contrary, FISSION study [4] including SOF plus ribavirin for genotype 2 had shown that ribavirin exposure was a significant factor for SVR (odds ratio 1.258). [...]another even more remarkable difference was that the IFNL4 gene (previous mistakenly refer to IL28B, rs12979860) C/C constituted the 33-47% of total study population in the pivotal study patients [4,5]. The individuals in this study had genotype 1 or 4 HCV infection and received SOF+PEG-IFN+R. The frequency of the rs12979860 favorable C/C alleles varies broadly across different populations, allele frequency was nearly 0.9 in East Asians, followed by Caucasians (0.63) and Hispanics (0.55), and is the least common in patients of African origin (0.39). In a Korean study [11], SVR rate were 97% in subjects with C/C allele and 96% in non-CC alleles. Since there are too many DAA treatment options and those SVR rates are excellent, there will be low possibility to prove clinical significance of SOF+R treatment in future trials.
ISSN:2287-2728
2287-285X
DOI:10.3350/cmh.2018.1009